Rhythm Pharmaceuticals, Inc. (RYTM)
NASDAQ: RYTM · Real-Time Price · USD
104.60
-1.10 (-1.04%)
At close: Dec 5, 2025, 4:00 PM EST
105.34
+0.74 (0.71%)
After-hours: Dec 5, 2025, 6:15 PM EST
Rhythm Pharmaceuticals Stock Forecast
Stock Price Forecast
The 13 analysts with 12-month price forecasts for Rhythm Pharmaceuticals stock have an average target of 118.46, with a low estimate of 94 and a high estimate of 142. The average target predicts an increase of 13.25% from the current stock price of 104.60.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Rhythm Pharmaceuticals stock from 13 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 8 | 8 | 8 | 8 |
| Buy | 4 | 5 | 5 | 5 | 5 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 13 | 13 | 13 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Initiates $136 | Strong Buy | Initiates | $136 | +30.02% | Nov 25, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $105 → $114 | Strong Buy | Maintains | $105 → $114 | +8.99% | Nov 10, 2025 |
| Needham | Needham | Strong Buy Maintains $122 → $120 | Strong Buy | Maintains | $122 → $120 | +14.72% | Nov 7, 2025 |
| Needham | Needham | Strong Buy Maintains $95 → $122 | Strong Buy | Maintains | $95 → $122 | +16.63% | Nov 4, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $157 → $139 | Strong Buy | Maintains | $157 → $139 | +32.89% | Oct 17, 2025 |
Financial Forecast
Revenue This Year
191.73M
from 130.13M
Increased by 47.34%
Revenue Next Year
301.37M
from 191.73M
Increased by 57.18%
EPS This Year
-3.24
from -4.34
EPS Next Year
-2.55
from -3.24
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 202.2M | 378.7M | ||||
| Avg | 191.7M | 301.4M | ||||
| Low | 181.3M | 257.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 55.4% | 97.5% | ||||
| Avg | 47.3% | 57.2% | ||||
| Low | 39.3% | 34.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -3.03 | -0.74 | ||||
| Avg | -3.24 | -2.55 | ||||
| Low | -3.27 | -3.58 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.